I like BMY here. I already own shares, but am adding a call spread.
Obviously, I am chasing short-term a bit, which is not generally a good idea. In this case I am willing to take the risk because of the overhead gap in volume (it's not a true gap, of course), and the fact that the stock seems ready to break its long-term down trend.
Fundamentally, I think the strength is supported by good earnings, low P/E, a rich dividend, and recent successes in drug trials. The reason for the longer-term weakness is the threat of blockbuster drugs losing their protection from generics, and increased leverage, due to the company buying out smaller biotechs to improve its drug pipeline.
I added a March 24, 54/56 call spread, currently priced at 60¢.
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.